Ziwig's Endotest® Receives Fast-Track Reimbursement for 25,000 Women in France
In a groundbreaking move, French biotech company Ziwig has announced the fast-track reimbursement of its Endotest®, the world's first saliva-based diagnostic test for endometriosis. This significant step will make the test available to approximately 25,000 patients across 80 medical centers in France. Announced on February 11, 2025, the initiative follows a decree from French health authorities aimed at improving diagnostic processes for this often-misunderstood condition.
Endometriosis, a condition that impacts around one in ten women worldwide, is notorious for its myriad symptoms that can interfere with quality of life and fertility. Unfortunately, the diagnostic journey for many women can extend between 7 and 10 years, during which time they navigate through various medical consultations and procedures, leading to prolonged pain and suffering. The fast-tracking of reimbursement for the Ziwig Endotest® promises to alleviate this 'diagnostic wandering' by providing a reliable and non-invasive diagnostic tool, with results delivered in just a few days.
Ziwig Endotest® boasts impressive statistical validation, demonstrating a 97.4% sensitivity and a specificity of 93.5% in detecting various forms of endometriosis, including early peritoneal cases. This means that the test can effectively identify the presence of endometriosis sooner, enabling healthcare providers to initiate treatment more rapidly and improve the overall management of the condition.
The test’s non-invasive nature offers a compelling alternative to traditional diagnostic methods, such as laparoscopic surgery, which can be both uncomfortable and expensive. Early diagnosis plays a crucial role in fertility preservation and better management of the disease. With increasing recognition and availability in countries such as Germany, Switzerland, and the UK, Ziwig Endotest® is quickly becoming an essential tool in women's health management across Europe and beyond.
Ziwig's mission of advancing women's health is further supported by the Innovation Funding program, designed to enhance access to groundbreaking medical technologies that address significant health challenges or reduce costs in healthcare. Yahya El Mir, CEO and Founder of Ziwig, expressed his enthusiasm for the initiative, stating, "With Ziwig Endotest®, we are determined to end the unacceptable diagnostic wandering that leaves many women in pain. The coverage of Ziwig Endotest® in 80 centers in France, made possible by the French health authorities, marks a breakthrough for both patients and healthcare practitioners."
Following the successful delegation in France, Ziwig plans to expand the availability of the Endotest® to countries like India, Romania, and Brazil in the near future. The growing acceptance and regulation of such innovative diagnostic tools reflect a positive shift in the healthcare system towards prioritizing women's health needs.
As Ziwig looks ahead, its research continues to explore how salivary RNA paired with artificial intelligence (AI) can further revolutionize the diagnosis and management of gynecological conditions, such as ovarian masses and amyotrophic lateral sclerosis (ALS). Recognized for its contributions to health innovation with the prestigious 2024 Galien International Prize and supported by the France 2030 plan, Ziwig is poised to make a lasting impact on women's health and well-being.
Endometriosis, a condition that impacts around one in ten women worldwide, is notorious for its myriad symptoms that can interfere with quality of life and fertility. Unfortunately, the diagnostic journey for many women can extend between 7 and 10 years, during which time they navigate through various medical consultations and procedures, leading to prolonged pain and suffering. The fast-tracking of reimbursement for the Ziwig Endotest® promises to alleviate this 'diagnostic wandering' by providing a reliable and non-invasive diagnostic tool, with results delivered in just a few days.
Ziwig Endotest® boasts impressive statistical validation, demonstrating a 97.4% sensitivity and a specificity of 93.5% in detecting various forms of endometriosis, including early peritoneal cases. This means that the test can effectively identify the presence of endometriosis sooner, enabling healthcare providers to initiate treatment more rapidly and improve the overall management of the condition.
The test’s non-invasive nature offers a compelling alternative to traditional diagnostic methods, such as laparoscopic surgery, which can be both uncomfortable and expensive. Early diagnosis plays a crucial role in fertility preservation and better management of the disease. With increasing recognition and availability in countries such as Germany, Switzerland, and the UK, Ziwig Endotest® is quickly becoming an essential tool in women's health management across Europe and beyond.
Ziwig's mission of advancing women's health is further supported by the Innovation Funding program, designed to enhance access to groundbreaking medical technologies that address significant health challenges or reduce costs in healthcare. Yahya El Mir, CEO and Founder of Ziwig, expressed his enthusiasm for the initiative, stating, "With Ziwig Endotest®, we are determined to end the unacceptable diagnostic wandering that leaves many women in pain. The coverage of Ziwig Endotest® in 80 centers in France, made possible by the French health authorities, marks a breakthrough for both patients and healthcare practitioners."
Following the successful delegation in France, Ziwig plans to expand the availability of the Endotest® to countries like India, Romania, and Brazil in the near future. The growing acceptance and regulation of such innovative diagnostic tools reflect a positive shift in the healthcare system towards prioritizing women's health needs.
As Ziwig looks ahead, its research continues to explore how salivary RNA paired with artificial intelligence (AI) can further revolutionize the diagnosis and management of gynecological conditions, such as ovarian masses and amyotrophic lateral sclerosis (ALS). Recognized for its contributions to health innovation with the prestigious 2024 Galien International Prize and supported by the France 2030 plan, Ziwig is poised to make a lasting impact on women's health and well-being.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.